Duvelisib: Phase II data

Top-line data from the open-label, international Phase II DYNAMO trial in 129 patients with follicular lymphoma (n=83), small lymphocytic lymphoma (SLL) (n=28) or marginal zone lymphoma (n=18) who are refractory to Rituxan rituximab and to either chemotherapy or radioimmunotherapy showed that twice-daily 25 mg oral duvelisib for up to thirteen 28-day cycles led to an ORR of 46%, all of which were partial responses. Duvelisib led to an ORR of 41% in patients with follicular lymphoma, 68% in patients with SLL and 33% in patients with marginal zone lymphoma. Infinity said it had “hoped that treatment with duvelisib as a monotherapy would have provided a larger clinical benefit” for patients with advanced indolent NHL. ...